INTRODUCTION {#sec1-1}
============

Diffuse alveolar hemorrhage (DAH) is a rare clinical entity which refers to bleeding into the acinar portion of the lung from the pulmonary microvasculature.\[[@ref1]\] This occurs as a result of the disruption of the alveolar--capillary basement membrane, leading to the intra-alveolar collection of red blood cells. The prognosis of patients with DAH is often dismal, and the in-hospital mortality ranges widely from 20% to 100%.\[[@ref2]\] A strong clinical suspicion is often required for making an early diagnosis to prevent disease progression and reduce the mortality rate.\[[@ref1]\]

A wide spectrum of clinical conditions are known to cause DAH. This includes immunological mediated conditions such as systemic vasculitis (granulomatosis with polyangitis \[Wegner\'s granulomatosis\], microscopic polyangitis), rheumatoid arthritis, systemic lupus erythematosus (SLE), antiglomerular basement membrane antibody disease (Goodpasture syndrome), antiphospholipid syndrome, and Bechet\'s disease. The nonimmunological mediated conditions include drugs, toxins, bleeding disorders, and malignancy.\[[@ref1][@ref3]\]

Anticoagulants are increasingly being used in a variety of clinical conditions, and bleeding forms an important adverse effect of anticoagulant use. DAH due to warfarin is an uncommon clinical entity and has been infrequently documented in the literature.\[[@ref4]\] The paucity of the literature on the subject prompted this report of a young male who presented with hemoptysis and was subsequently diagnosed with DAH as a result of warfarin therapy.

CASE REPORT {#sec1-2}
===========

A 27-year-old, HIV-negative, never-smoker male presented to the emergency department with complaints of hemoptysis along with shortness of breath for the past 3 days. His clinical course was characterized by multiple bouts of coughing out bright red blood around 200 ml/day for 3 days. Hemoptysis was not accompanied with malena, bleeding diathesis, and gum or nasal bleed. In addition, he also had symptoms of dyspnea at rest, which were not associated with wheezing. One month prior to presentation, he had complained of exertional dyspnea accompanied with pain and swelling in the right leg for which he underwent a computed tomography scan of the chest. At that point, a diagnosis of pulmonary embolism along with right lower-limb deep-venous thrombosis was made. He was started on oral anticoagulants (tablet warfarin: 5 mg/day) after an adequate overlap with low-molecular-weight heparin. However, the patient had been taking the drug erratically without adequate monitoring for a month prior to presentation. General physical examination revealed a young male in respiratory distress with a saturation of 90% while breathing ambient room air. There was an asymmetry in the girth of the lower limbs, with right limb girth being larger. Chest auscultation revealed vesicular breath sounds of equal intensity with bibasilar fine-end inspiratory crepitation.

Investigations {#sec2-1}
--------------

On admission, the hemoglobin levels were 14.2 gm% which subsequently fell to 10.6 gm% over the course of 3 days. Liver and renal function tests as well as the urine routine analysis were within the normal limits. The prothrombin time (PT) values done on admission were deranged with an international normalized ratio (INR) of 7.2. A review of the past records revealed PT values of 22 and an INR of 2.05 at the time of discharge. Chest radiograph done on presentation revealed bilateral upper-zone infiltrates (right \> left). Contrast-enhanced computed tomography of the chest revealed bilateral eccentric filling defects in the pulmonary artery suggestive of pulmonary thromboembolism \[[Figure 1a](#F1){ref-type="fig"}\]. In addition, the high-resolution computed tomography of the chest showed bilateral upper-lobe ground-glass opacities with a mosaic attenuation pattern \[[Figure 1b](#F1){ref-type="fig"}\]. Compression ultrasound (CUS) along with Doppler of the right lower limb revealed partial recanalized thrombus in the right common femoral vein with streaky irregular patchy flow. In view of the presence of diffuse alveolar infiltrates, the patient\'s consent was taken for a fiber-optic bronchoscopy which revealed a normal tracheobronchial tree. Serial bronchoscopic alveolar lavage (BAL) was done from the right upper lobe, with each of the five sequential 20-mL aliquots of BAL being bloodier than the previous \[[Figure 2](#F2){ref-type="fig"}\]. Cytological evaluation of the BAL sample revealed numerous brown intracytoplasmic hemosiderin pigment-laden macrophages on hematoxylin and eosin stain \[[Figure 3a](#F3){ref-type="fig"}\] and bluish cytoplasmic granules on Pearls stain \[[Figure 3b](#F3){ref-type="fig"}\]. Stains and cultures of the BAL were negative for Mycobacterium tuberculosis and other aerobic organisms as well as pathogenic fungi. Subsequent workup included a negative test for antineutrophil cytoplasmic antibodies, antinuclear antibody, antiglomerular basement membrane, and antiphospholipid antibodies. A diagnosis of anticoagulant (warfarin)-induced DAH was made based on (a) clinical presentation; (b) radiology; and confirmed on (c) BAL as well as BAL fluid cytology.

![(a) Contrast-enhanced computed tomography of the chest (mediastinal window: coronal section) showing eccentric filling defects in the right and left main pulmonary arteries suggestive of pulmonary thromboembolism. (b) High-resolution computed tomography of the chest (lung window: axial section) showing bilateral upper-lobe ground-glass opacities with a mosaic attenuation pattern](LI-36-534-g001){#F1}

![Serial broncho-alveolar lavage showing progressive hemorrhagic nature of the broncho-alveolar lavage fluid](LI-36-534-g002){#F2}

![(a) High-power view (H and E, ×40) of the patient\'s broncho-alveolar lavage fluid cytology specimen showing numerous brown intracytoplasmic hemosiderin pigment-laden macrophages (black arrows). (b) High-power view (Pearls, ×40) of the patient\'s broncho-alveolar lavage fluid cytology specimen showing hemosiderin-laden macrophages. Hemosiderin is demonstrated as blue cytoplasmic granules](LI-36-534-g003){#F3}

Management {#sec2-2}
----------

Warfarin was immediately stopped, and the patient was placed on high-flow oxygen and 10-mg intravenous Vitamin K injection was administered followed by transfusion of four units of fresh frozen plasma. In a couple of days, the patient had improvement in his symptoms, and he was weaned off the supplemental oxygen. A repeat chest radiograph done on day 4 showed clearance of the radiological opacities. As the patient was unable to afford newer oral anticoagulants, he was discharged on a lower dose of warfarin with an advice of strict INR monitoring in further follow-ups.

DISCUSSION {#sec1-3}
==========

The clinical presentation in patients with DAH includes cough, hemoptysis, dyspnea, and chest pain.\[[@ref1]\] Hemoptysis may be absent in one-third of patients with DAH.\[[@ref5]\] Respiratory failure is usually the most severe form of presentation requiring ventilatory support and entailing high mortality rate. The diagnosis of DAH is mainly clinical in an appropriate setting and is usually supported by radiological and bronchoscopic findings.\[[@ref3]\] Clinical history forms an important diagnostic armamentarium in patients with DAH, as apart from establishing a diagnosis, it often elicits the etiology. Radiological features in DAH are usually nonspecific and include patch/diffuse ground-glass opacities, "crazy-paving" pattern, or frank consolidation. These findings are often seen in acute pulmonary edema, acute respiratory distress syndrome (ARDS), congestive heart failure, and infections.\[[@ref1]\] BAL often confirms the diagnosis based on (1) progressively bloodier return on sequential BAL samples and (2) hemosiderin-laden macrophages on BAL cytology.\[[@ref1][@ref3]\]

Based on the histological pattern, the causes of DAH may be grouped as: (1) those associated with pulmonary capillaritis; (2) associated with bland pulmonary hemorrhage; and (3) associated with diffuse alveolar damage.\[[@ref1]\] Pulmonary capillaritis refers to the neutrophilic infiltration of the pulmonary capillaries leading to loss of structural integrity and bleeding into the alveolar spaces. This is usually seen in DAH associated with systemic vasculitis, Goodpasture syndrome, rheumatoid arthritis, some drugs (diphenylhydantoin, propylthiouracil, and all--trans-retinoic acid), and the rare entity of idiopathic pulmonary capillaritis. In patients with bland pulmonary hemorrhage, there occurs bleeding into the alveolar spaces without affecting the interstitial compartment. This is often seen in patients with mitral stenosis, bleeding disorders, and anticoagulant therapy. Diffuse alveolar damage is usually seen in patients with SLE, cytotoxic drug intake, and ARDS.\[[@ref6]\]

Anticoagulant-induced DAH is a rare clinical entity and has been infrequently documented in the medical literature. Warfarin is a Vitamin K antagonist and a very potent and widely used anticoagulant. Systemic bleeding is often an important complication with warfarin therapy.\[[@ref7]\] The risks of bleeding further increase because factors such as diet, concurrent medications, poor compliance, and alcohol consumption lead to fluctuating INR levels.\[[@ref8]\] A search of the literature using PubMed, Cochrane, IndMed, Google, and other databases with the keywords "warfarin," "acenocoumarol," "Vitamin K antagonist," and "diffuse alveolar haemorrhage" revealed 18 studies\[[@ref4][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25]\] documenting 22 patients, which has been depicted in [Table 1](#T1){ref-type="table"}. Brown *et al*.\[[@ref9]\] in 1965 for the first time reported DAH caused due to warfarin in a 64-year-old male who presented with hemoptysis and hematuria. He had accidentally ingested 35 mg of warfarin leading to DAH, a diagnosis of which was made clinicoradiologically. Nearly, a decade later, Finley *et al*.\[[@ref10]\] reported three patients with warfarin-induced "occult pulmonary hemorrhage," the diagnosis of which was established on BAL. Following this, isolated reports have come up highlighting this rare clinical entity.\[[@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25]\] A recent retrospective study from Japan\[[@ref24]\] described the clinical features and outcome of DAH caused by antithrombotic therapy. In this study, 14/39 patients had DAH due to warfarin, with eight on monotherapy, whereas the remaining six were on other antithrombotic agents too. Of the eight patients on warfarin monotherapy, only four had DAH due to the offending drug, whereas the remaining four had other causes too (vasculitis and heart failure).

###### 

Tabulated review of anticoagulant-induced diffuse alveolar hemorrhage

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/years                                                        Patients/age                          Symptoms                                                          Drug/dosage                                                                                       Chest radiograph                                                                                               Computed tomography chest                                                                                 Fiber-optic bronchoscopy                              Management/outcome
  ------------------------------------------------------------------- ------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------------------------------------------------
  Brown*et al*., 1965\[[@ref9]\]                                      1/64 years                            Hemoptysis, hematuria ×24 h                                       Warfarin -- 35 mg                                                                                 Bilateral alveolar pulmonary infiltrate                                                                        Not done                                                                                                  Not done                                              Oral/IV Vitamin K survived

  Finley*et al*., 1975\[[@ref10]\]                                    2\                                    Progressive malaise, chest pain, and dyspnea\                     Warfarin -- dose NA\                                                                              Bilateral lower-lobe infiltrates\                                                                              Not doneNot done                                                                                          Done (bloody lavage fluid)\                           Warfarin withdrawal/survived\
                                                                      Patient 1: 69 years\                  Acute onset of dyspnea                                            Warfarin (post-MVR)                                                                               Diffuse infiltrates                                                                                                                                                                                                      Done (bloody lavage fluid)                            Warfarin stopped/survived
                                                                      Patient 2: 42 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Granthil*et al*., 1981 (French) (abstract in English)\[[@ref11]\]   2 (individual detail not available)   Malena, epistaxis, dyspnea, acute respiratory distress syndrome   Oral anticoagulant (details not available)                                                        Diffuse micronodular military pattern                                                                          Not done                                                                                                  Done (large number of alveolar siderophages)          No details available

  Barnett*et al*., 1992\[[@ref12]\]                                   1/27-year-old female                  Fever. dyspnea, cough, and hemoptysis                             Brodifacoum (DCon) -- "superwarfarin" ingestion                                                   Diffuse alveolar infiltrates                                                                                   Not done                                                                                                  Not done                                              FFP, 60 mg of IVVitamin K , mechanical ventilation/survived

  Erdogan*et al*., 2004\[[@ref13]\]                                   1/75-year-old male                    Fever, severe dyspnea, dizziness, and hemoptysis                  Warfarin: 5 mg/day for AF                                                                         Bilateral alveolar infiltration                                                                                Bilateral alveolar infiltration compatible with bilateral alveolar hemorrhage                             Hemosiderin-filled histiocytes                        100% oxygen, 2 units of FFP, and 30-mg Vitamin K IV/survived

  Thomas*et al*., 2008\[[@ref14]\]                                    1/60-year-old male                    Fever, cough, severe breathlessness, and hemoptysis               Warfarin 5 mg daily for MVR                                                                       Bilateral fluffy opacities                                                                                     Diffuse pulmonary alveolar hemorrhage                                                                     Not done                                              FFP, mechanical ventilation/died within 2 h

  Klenner*et al*., 2008\[[@ref15]\]                                   1/84-year-old female                  Hemoptysis                                                        Phenprocoumon for AVR and AF                                                                      Diffuse alveolar infiltrates                                                                                   \-                                                                                                        Fresh blood in all segments corresponding to DAH      Blood transfusion and application of 100 IU Vitamin K-dependent blood clot factors

  Mogili*et al*., 2009\[[@ref16]\]                                    1/29-year-old female                  Dyspnea, hypoxia                                                  Coumadin for DVT: Dose not mentioned                                                              Bilateral interstitial markings of the lungs, with a diffuse nodular pattern                                   Diffuse ill-defined interstitial opacities with nodular appearance                                        Bloody aliquots consistent with DAH                   IV steroids/survived

  Yardan*et al*., 2012 (Turkish) (abstract in English)\[[@ref17]\]    1/58-year-old female                  Dyspnea, cough, and hemoptysis×2 days                             Warfarin for AF                                                                                   Done (details NA)                                                                                              Done (details NA)                                                                                         Done (details NA)                                     Done (details NA)

  Waness *et al*., 2009\[[@ref4]\]                                    1/62-year-old female                  Hemoptysis and dyspnea×24 h                                       Warfarin for AF: 5 mg PO every other day (4 days/week), 2.5 mg PO every other day (3 days/week)   Alveolar opacities in both lungs, especially in perihilar and pericardiac zones                                Bilateral patchy airspace disease                                                                         Done (lavage became progressively more hemorrhagic)   FFP, Vitamin KMechanical ventilation X14 days/survived

  Itoh*et al*., 2011\[[@ref18]\]                                      1/72-year-old male                    Hemoptysis and dyspnea                                            Warfarin 2 mg/day                                                                                 Bilateral alveolar infiltration                                                                                Bilateral ground-glass opacities and multiple low-attenuation areas                                       BAL: HemorrhagicHemosiderin-filled macrophages        10-mg Vitamin K IV/survived

  Baba*et al*., 2012\[[@ref19]\]                                      1/85-year-old male                    Dyspnea and blood-stained frothy sputum                           Warfarin for AF: Alternate day dosing -- 5 and 6 mg once daily                                    Widespread airspace shadowing in both lungs with some relative sparing of the apices and costophrenic angles   Widespread ground-glass opacity with superimposed interlobular thickening and "crazy paving" appearance   Not done                                              IV Vitamin K/survived

  Lee and Kim, 2013\[[@ref20]\]                                       1/56-year-old male                    Aggravated dyspnea×24 h                                           Warfarin: 2.0--2.5 mg×5 months for pulmonary vein thrombosis                                      Bilateral pulmonary infiltrations                                                                              Extensive ground-glass attenuations and "crazy-paving appearance"                                         Done (lavage became progressively more hemorrhagic)   10-mg Vitamin K, FFPs, mechanical ventilation, ECMO/survived

  Uysal*et al*., 2014\[[@ref21]\]                                     1/49-year-old male                    Dyspnea and hemoptysis×2 h                                        Warfarin: 0.5 mg/day for MVR                                                                      Diffuse alveolar infiltrates                                                                                   Bilateral alveolar infiltration                                                                           Not done                                              Supplemental oxygen, IVVitamin K and FFP/survived

  Kaya*et al*., 2015\[[@ref22]\]                                      1/59-year-old male                    Hemoptysis and shortness of breath×24 h                           Warfarin 2.5 mg/day for MVR                                                                       Alveolar opacities in both lungs                                                                               Bilateral patchy airspace disease                                                                         Done (no details)                                     FFP and RBC transfusions/survived

  Heffler *et al*., 2016\[[@ref23]\]                                  1/64-year-old male                    Hemoptysis, cough, and dyspnea                                    Warfarin for AF: 5 mg/day                                                                         Chronic signs of emphysematous\                                                                                Diffuse bilateral signs of alveolar hemorrhage with hydroaerial levels within emphysematous cysts         Not done                                              10 mg IV\
                                                                                                                                                                                                                                                                                Chronic obstructive pulmonary disease                                                                                                                                                                                                                                          Fitomenadione, FFP, 1 g IV pulse dose of methylprednisolone, and supplemental oxygen/survived

  Otoshi*et al*., 2016\[[@ref24]\]                                    4                                     Clinical details NA                                               Clinical details NA                                                                               Clinical details NA                                                                                            Clinical details NA                                                                                       Clinical details NA                                   Clinical details NA

  D'Amore*etal*., 2017\[[@ref25]\]                                    1/62-year-old male                    Shortness of breath and fever×2 days, massive hemoptysis          Warfarin for AF: Dose not mentioned                                                               Left lower-lobe infiltrate                                                                                     Not done                                                                                                  BAL: Hemosiderin-laden macrophages                    Two units of fresh frozen plasma and IV Vitamin K, intubation/died after 7 days
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AVR: Aortic valve replacement, AF: Atrial fibrillation, DAH: Diffuse alveolar hemorrhage, DVT: Deep-venous thrombosis, FFPs: Fresh frozen plasma, IV: Intravenous, MVR: Mitral valve replacement, NA: Not available, BAL: Bronchoscopic alveolar lavage, ECMO: Extracorporeal membrane oxygenation

Management of warfarin-induced DAH is usually supportive, with withdrawal of the offending drug being the most important treatment strategy followed by administration of Vitamin K and fresh frozen plasma which serves as an effective antidote.\[[@ref1][@ref3][@ref4]\] Since DAH is often a life-threatening condition, a prompt diagnosis and early treatment is often required to decrease the mortality. Intravenous corticosteroids and ventilatory support are often required in cases with severe hypoxemia and respiratory failure. In a recent report,\[[@ref20]\] extracorporeal membrane oxygenation has been used as a bridge to therapy in severe cases of DAH caused due to warfarin therapy with promising results.

Our case highlights two important features related to the diagnosis and management of drug-induced DAH. First, a high index of clinical suspicion is warranted for an early and prompt diagnosis as was seen in our case. BAL is often considered to be the gold standard and was used in our case to confirm the diagnosis. Second, DAH has a high mortality rate and hence, therapy should be instituted as early as possible, with reversal of anticoagulation being the cornerstone of the management strategy.
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